KITOV PHARMA LT/S (KTOV) Lifted to Hold at Zacks Investment Research
According to Zacks, “Kitov Pharmaceuticals Holdings Ltd. is a pharmaceutical company which focused on the development of therapeutic candidates. The company’s product candidate consists of KIT-302, is formulated for treatment of pain caused by osteoarthritis and hypertension, which can be pre-existing or caused by the treatment for OA. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel. “
NASDAQ:KTOV opened at $1.13 on Tuesday. The company has a market cap of $17.33 million, a PE ratio of 2.90 and a beta of 4.42. KITOV PHARMA LT/S has a 52 week low of $0.56 and a 52 week high of $3.81.
About KITOV PHARMA LT/S
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.
Read More: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.